A Controlled Human Pneumococcal Infection Model (PIM) Study

Streptococcus Pneumoniae Infection Clinical Trial

— PIM  

Official title:

A Controlled Human Pneumococcal Infection Model (PIM) Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05361499
• Other study ID #: NL79171.091.22
• Status: Completed
• Phase: N/A
• Start date: May 31, 2022
• Est. completion date: February 16, 2023

Study information

• Verified date: April 2022
• Source: Radboud University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly. Although pneumococcal vaccines exist, they do not provide complete protection and new strategies to combat this pathogen are urgently needed. Asymptomatic infection of S. pneumoniae in the human nasopharynx precedes the development of pneumococcal disease. Previously, an Experimental Human Pneumococcal Carriage (EHPC) model has been developed at the Liverpool School of Tropical Medicine (LSTM). The current study entails to establish this model in healthy adults living in the Netherlands using the inoculation dose currently used at LSTM.

Healthy adult participants (M/F) will be inoculated intranasally with strain BHN418, a penicillin sensitive serotype 6B strain of S. pneumoniae that was previously isolated from a healthy carrier. Following inoculation, participants will be monitored and blood and nasal samples will be collected over a period of 28 ± 3 days. Participants will receive a course of amoxicillin to eradicate infection on or shortly after the last visit at day 28 ± 3, unless S. pneumoniae is not detected on both day 14 and 28 ± 3 post-inoculation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 16, 2023
• Est. primary completion date: February 16, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

1. Participant is aged = 18 and < 50 years on the day of the baseline visit.

2. Participant is in good health as confirmed by review of medical history and physical examination.

3. Participant has adequate understanding of the procedures of the study and agrees to abide strictly thereby.

4. Participant has a home address within the Netherlands.

5. Participant is fully conversant in the Dutch language

6. Participant is able to communicate easily by both mobile telephone and text messaging

7. Participant is available to attend all study visits.

8. Participant agrees to inform his/her general practitioner (GP), in case applicable, about participation in the study and signs a request to release any relevant medical information concerning possible contra-indications for participation in the study by the GP.

9. Participant agrees to provide access to information regarding the vaccination background

10. Participant agrees to provide a treating physician access to all study-related information and data in case an adverse event occurs

11. Participant is able to arrive within 3h at the Radboudumc at any time during the study participation and participant is able to arrive within 1h at the Radboudumc from his/her home address. The participant must have a home address and live in the Netherlands.

12. Participant is willing to take an antibiotic regiment after inoculation with S. pneumoniae according to the study protocol.

13. Participant has signed informed consent.

14. Participant is able to answer all questions of the pre-consent questionnaire correctly.

Exclusion Criteria:

1. Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results.

2. Smoking: Any smoking event in the last month, including (e-)cigarette, joint, cigar and pipe

3. Previous pneumococcal vaccination or infection with the pneumococcus at screening or inclusion visit

4. Close physical contact with at risk individuals, i.e. children under 5 years of age, immunosuppressed adults, frail elderly, chronically ill individuals. Close physical contact is defined as:

• living in the same household

• having work-related contact

• spending more than 1 hour/day together with an at risk individual at less than 1.5 meter distance.

5. Illness at screening visit, illness at baseline (including mild upper respiratory tract infection, common cold, running nose), acute illness within 3 days prior to inoculation

6. Any antibiotic treatment within 2 weeks before inoculation

7. For female participants: pregnancy, lactation or intention to become pregnant during the study. Female volunteers are required to use an effective form of contraception during this study.

8. Known hypersensitivity to or contra-indications (including co-medication) for use of penicillin

9. Receipt of any vaccinations in the two weeks prior to the start of the study (inoculation) or plans to receive any other vaccinations during the study period.

10. Participation in any other clinical study (unless observational) in the three months prior to the start of the study or during the study period.

11. Being an employee or student of the department of Laboratory Medicine, Radboudumc.

12. Any other condition or situation that would, in the opinion of the investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Pneumococcal Infections
• Pneumonia
• Pneumonia, Pneumococcal
• Streptococcus Pneumoniae Infection

Intervention

Biological:
• Sp_6B
Intranasal inoculation of Streptococcus pneumoniae serotype 6B, 160,000 colony forming units (CFU)

Drug:
• Amoxicillin 500 mg
Amoxicillin, 7 days, 2x 500 mg

Locations

Country	Name	City	State
Netherlands	Radboudumc	Nijmegen

Sponsors (1)

Lead Sponsor	Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Bacterial load as determined by PCR of pneumococcal genes at each sampling time point		On day 3, 7, 14 and 28 after inoculation
Other	Cellular responses in blood and mucosal samples at various timepoints		On day 3, 7, 14 and 28 after inoculation
Other	Soluble mediators in mucosal or blood samples at various timepoints		On day 3, 7, 14 and 28 after inoculation
Other	Expression level of host genes at various timepoints		On day 3, 7, 14 and 28 after inoculation
Other	Expression level of S. pneumoniae genes at various timepoints		On day 3, 7, 14 and 28 after inoculation
Other	Presence of species other than S. pneumoniae in nasal washes at various timepoints		On day 3, 7, 14 and 28 after inoculation
Primary	Percentage of volunteers infected with S. pneumoniae serotype 6B following inoculation.		up to 4 weeks after inoculation
Secondary	The number of participants with sollicited AEs that are related to infection		from the baseline visit (between day -1 and -6) till the end of the study (day 28 ± 3)
Secondary	The number, type and severity of sollicited AEs that are related to infection		from the baseline visit (between day -1 and -6) till the end of the study (day 28 ± 3)
Secondary	Number of sampling timepoints with S. pneumoniae culture-positive nasal wash samples post-inoculation		On day 3, 7, 14 and 28 after inoculation
Secondary	Number of colony forming units (CFUs) per ml detected in nasal wash of infected participants at each sampling timepoint		On day 3, 7, 14 and 28 after inoculation
Secondary	Concentrations of S. pneumoniae-specific antibodies in blood and mucosal samples at the various sampling time points		On day 3, 7, 14 and 28 after inoculation